BMS-986012 + Carboplatin + Etoposide + Nivolumab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Mar 17, 2021 → Dec 31, 2025
NCT ID
NCT04702880About BMS-986012 + Carboplatin + Etoposide + Nivolumab
BMS-986012 + Carboplatin + Etoposide + Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Extensive-stage Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04702880. Target conditions include Extensive-stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04702880 | Phase 2 | Active |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer